MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- CIPLA
CIPLA Share Price 
(CIPL)
Here is the latest stock price and chart of Cipla. For more details, see the Cipla company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Mar 18, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)534.55 | Open (Rs) 534.00 | High (Rs) 536.25 | Low (Rs) 529.05 |
| % Change0.53 | Volume 43,076 | Value (Rs) 22,975,257 | 52-Week H/L 678.00 / 483.75 |
| Live NSE Quotes | Mar 18, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)534.50 | Open (Rs) 533.05 | High (Rs) 535.80 | Low (Rs) 529.00 |
| % Change0.36 | Volume 1,266,863 | Value (Rs) 675,790,419 | 52-Week H/L 678.45 / 483.75 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 16.02 | P/E Ratio (x) 33.37 | Market Cap (Rs m) 429,890.46 | P/BV (x) 3.02 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
CIPLA Share Price Today:
CIPLA last traded price was up 0.5% to Rs 534.6 on the BSE. On the NSE, CIPLA last traded price was up 0.4% to Rs 534.5. The total volume of shares traded was 1.3 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.2%. And the benchmark S&P BSE SENSEX was at 38,095.1 (up 0.2%).
Over the last 30 days, the CIPLA share price is down 1.3%. And over the last one year, CIPLA share price is down 4.4%.
|
| |
Today's Market
Sensex Ends Marginally Higher; Realty and Energy Stocks Witness Buying(Closing)
Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector.
Related Views On News
CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)
Nov 12, 2018 | Updated on Nov 12, 2018For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.
Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)
Nov 10, 2017Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.
Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)
Oct 30, 2017Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)
Mar 8, 2019History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?
Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)
Mar 7, 2019Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...
The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)
Mar 7, 2019India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?
Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)
Mar 6, 2019Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?
The Jet Airways Crisis in 6 Charts(Sector Info)
Mar 5, 2019What happened to Jet Airways, once among top 3 airlines in India? Is it another Kingfisher in the making? Read on...
MoreTRACK CIPLA
- Track your investment in CIPLA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CIPLA
CIPLA - TEVA PHARMA COMPARISON
COMPARE CIPLA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.